BMC Cancer最新文献

{"title":"Impact of uterine adenomyosis on survival outcome of patients with non-endometrioid endometrial cancer.","authors":"Levent Ozgen, Yakup Yalcin, Merve Abay, Kemal Ozerkan","doi":"10.1186/s12885-025-14815-4","DOIUrl":"10.1186/s12885-025-14815-4","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1574"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12522866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors.","authors":"Jian Zhang, Xiaojun Liu, Yiqun Du, Yuxin Mu, Yanchun Meng, Yan Sun, Ling Zhang, Chris Chen, Marie Cullberg, Ethan Fan, Xichun Hu","doi":"10.1186/s12885-025-14982-4","DOIUrl":"10.1186/s12885-025-14982-4","url":null,"abstract":"<p><strong>Background: </strong>Capivasertib is recommended, plus fulvestrant, for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with PIK3CA/AKT1/PTEN alterations and is under development for further breast and prostate cancer indications. Pharmacokinetics in Western and Japanese patients have been previously characterized. We conducted a Phase I trial assessing the pharmacokinetics and safety of capivasertib, alone or plus paclitaxel, in Chinese patients with advanced solid tumors.</p><p><strong>Methods: </strong>In this open-label, fixed-sequence Phase I trial, Chinese patients with advanced solid tumors refractory or resistant to standard therapy received capivasertib alone (Part A) and then plus paclitaxel (Part B). The primary endpoint comprised capivasertib pharmacokinetics after a single dose (480 mg), or multiple doses given alone (480 mg twice daily [4 days on, 3 days off]) or plus paclitaxel (capivasertib 400 mg twice daily [4 days on, 3 days off], paclitaxel 80 mg/m² once weekly; both 3 weeks on, 1 week off). Safety was a secondary endpoint. Investigator-assessed best objective response was an exploratory endpoint.</p><p><strong>Results: </strong>Overall, 16 patients (median age 55.5 years, median weight 58.9 kg, 81.3% breast primary tumor location) received capivasertib alone in Part A and then capivasertib plus paclitaxel in Part B. The median time to maximum concentration, the geometric mean maximum plasma concentration, and the geometric mean area under the curve from time 0 to the last quantifiable concentration of capivasertib were: after a single dose (n = 16): 1.0 h, 1465 ng/mL, and 7243 h×ng/mL; after multiple doses (n = 15): 0.9 h, 2535 ng/mL, and 12,080 h×ng/mL; after multiple doses plus paclitaxel (n = 8): 1.9 h, 2467 ng/mL, and 12,830 h×ng/mL, respectively. After a single dose, the geometric mean terminal elimination half-life was 9.7 h. Hyperglycemia, diarrhea, and rash were the most common adverse events (reported for all patients). Most adverse events were Grade 1-2. Four (25.0%) patients achieved confirmed partial response and four (25.0%) stable disease as best objective response.</p><p><strong>Conclusions: </strong>Consistent with previous findings, capivasertib was absorbed rapidly and eliminated with a half-life of approximately 10 h. The manageable safety profile and preliminary antitumor activity support further investigation of capivasertib-containing combinations in Chinese patients with advanced solid tumors.</p><p><strong>Trial registration: </strong>The trial was registered at ClinicalTrials.gov with identifier no. NCT04742036. Date of registration: February 4, 2021.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1562"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12519771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RAS mutations and colorectal cancer metabolism: a metabolomic analysis of tissue samples.","authors":"Jianjiong Li, Buyuan Dong","doi":"10.1186/s12885-025-14994-0","DOIUrl":"10.1186/s12885-025-14994-0","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1580"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12522339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling GDF15 as a promising biomarker for predicting survival in pancreatic ductal carcinoma: a retrospective research.","authors":"Jianchun Xiao, Xiaoyue Lu, Wenhao Luo, Yicheng Wang, Taiping Zhang","doi":"10.1186/s12885-025-14963-7","DOIUrl":"10.1186/s12885-025-14963-7","url":null,"abstract":"<p><strong>Background: </strong>The prognosis of pancreatic ductal adenocarcinoma remains dismal, largely because this disease is typically diagnosed at an advanced stage, making early detection a major challenge. Beyond the conventional biomarker CA19-9, emerging evidence suggests the utility of additional markers for distinguishing PDAC from normal pancreatic tissue or chronic pancreatitis. Among these, Growth Differentiation Factor 15 (GDF15), implicated in various malignancies, has arisen as a promising candidate, particularly when expressed at elevated levels in pancreatic cancer. Recent insights into the oncogenic potential of GDF15 underscore its prognostic significance.</p><p><strong>Methods: </strong>In this study, a comprehensive analysis was performed by integrating clinicopathological data with GDF15 expression profiles from a retrospective clinical cohort. Immunohistochemical staining was used to quantify GDF15 expression in tissue samples, and expression levels were stratified using a prognosis-oriented threshold. Kaplan-Meier survival analysis was conducted to evaluate its association with overall survival.</p><p><strong>Results: </strong>GDF15 was found to be markedly overexpressed in PDAC tissues relative to adjacent normal pancreas, supporting its potential role in promoting tumor development. In addition, high GDF15 levels were significantly linked to unfavorable clinical outcomes, underscoring its value as a prognostic indicator in pancreatic cancer.</p><p><strong>Conclusions: </strong>The findings contribute novel insights into the role of GDF15, reinforcing its potential as a valuable prognostic biomarker for pancreatic cancer.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1569"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-recorded indexing measurements (PRIMS) - study protocol of a prospective observational cohort study to improve the accuracy of the diagnosis of cancer cachexia.","authors":"N D Hildebrand, M A T Sier, S M J van Kuijk, L S M Hoeijmakers, L L G C Ackermans, J Ubachs, L Stassen, N F M Ruber, V Schaghen-D'Antonio, E P Goedegebuure, L Baade-Corpelijn, B C Bongers, J Stoot, M Sosef, S Lambrechts, P J de Vos van Steenwijk, M Engelen, T Lubbers, T J Blokhuis, J A Ten Bosch, L Valkenburg-van Iersel, J de Vos-Geelen, M den Dulk, D P J van Dijk, S W M Olde Damink, S S M Rensen","doi":"10.1186/s12885-025-14979-z","DOIUrl":"10.1186/s12885-025-14979-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cachexia is a major challenge throughout cancer treatment. Unintentional weight loss, the principal diagnostic criterium of cancer cachexia, is usually assessed through self-reported body weight change, which may be prone to bias. Other aspects of cancer cachexia include altered body composition (e.g., loss of muscle mass) and impaired physical activity. The central aim of the 'Patient-Recorded Indexing MeasurementS' (PRIMS) study is to improve the accuracy of the diagnosis of cachexia in patients with cancer. The primary objectives are to compare self-reported and objectively measured pre-treatment weight changes, and to assess their respective association with treatment-related adverse events and survival. Secondary objectives are to define host phenotypes based on combinations of objectively assessed cachexia-related data that are predictive of treatment-related adverse events and survival, and to investigate longitudinal associations between body weight and physical activity patterns.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This prospective observational cohort study will be conducted in two Dutch referral centers specialized in treatment of patients with upper gastrointestinal, hepatobiliary, pancreatic, colorectal, and ovarian cancer. We will include 300 cancer patients scheduled for either neoadjuvant chemo(radio)therapy or upfront elective surgery. Patients will undergo a baseline assessment consisting of nutritional screening (anthropometry, body weight assessment), body composition analysis, and physical fitness tests. Patients will be provided with an accelerometer and weight scale for continuous/daily at-home measurements before, throughout, and after treatment. Treatment-related adverse events will be assessed according to the Common Terminology Criteria for Adverse Events or Clavien-Dindo classification. Response to chemo(radio)therapy will be assessed according to 'Response Evaluation Criteria in Solid Tumors' (RECIST) criteria. Disease-free and overall survival will be recorded. Relationships between cachexia-related parameters and outcomes will be investigated using multivariable logistic regression analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;The PRIMS protocol comprises a core assessment set of objective measurements to improve the diagnosis of cancer cachexia. It will help to identify patient phenotypes associated with treatment-related adverse events and survival. This approach is expected to advance cachexia diagnostics and enhance future clinical and translational research on the prevalence, severity, and impact of cancer cachexia. PRIMS will also aid clinicians in providing personalized counseling on treatment options and their expected outcomes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/strong&gt;Medical Ethics Committee of the Academic Hospital Maastricht/Maastricht University (azM/UM) (METC18012, version 4.0, June 2024), Netherlands Trial Register (NL65402.068.18). The trial is registered in the ClinicalT","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1572"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia.","authors":"Jinyan Chen, Zhihang Hu, Huigang Li, Renyi Su, Zuyuan Lin, Jianyong Zhuo, Chiyu He, Ruijie Zhao, Wei Shen, Yajie You, Shuhan Jiang, Xuyong Wei, Shusen Zheng, Xiao Xu, Di Lu","doi":"10.1186/s12885-025-14973-5","DOIUrl":"10.1186/s12885-025-14973-5","url":null,"abstract":"<p><strong>Objective: </strong>Developing a machine learning model to predict post-transplant muscle loss in hepatocellular carcinoma patients.</p><p><strong>Background: </strong>Liver transplantation is an effective treatment for selected HCC patients. However, severe muscle loss after liver transplantation is significantly associated with increased risk of mortality and recurrence. However, effective predictive methods remain inadequate.</p><p><strong>Methods: </strong>This study collected data from hepatocellular carcinoma patients who underwent liver transplantation over the past 2015 to 2020 at two hospitals. Propensity score matching and Cox regression analysis were conducted to establish muscle loss as an independent risk factor for recurrence. To construct the optimal predictive model for post-transplant muscle loss, we compared 50 machine learning models and use Recursive Feature Elimination to identify the most relative features.</p><p><strong>Results: </strong>Data from a total of 248 patients were collected. Kaplan-Meier analysis revealed a significant difference in prognosis between patients with and without sarcopenia before surgery. For patients without sarcopenia, postoperative muscle loss was identified as an independent risk factor for recurrence (HR = 2.38, P = 0.005). The best model was identified as the Imbalanced Random Forest, achieving an AUC of 0.832 on the non-sarcopenia cohort.</p><p><strong>Conclusions: </strong>A highly efficient model based on machine learning was developed to predict postoperative muscle loss in hepatocellular carcinoma patients undergoing liver transplantation, providing a valuable reference for the early detection of adverse events following the procedure.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1565"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12522249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The significant prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in digestive system cancers: a systematic review and meta-analysis.","authors":"Caihua Qian, Jingting Liu, Chunyan Meng, Jun Cheng, Bo Wu, Jianhua Liao","doi":"10.1186/s12885-025-15068-x","DOIUrl":"10.1186/s12885-025-15068-x","url":null,"abstract":"<p><strong>Background: </strong>Digestive system cancers are a major global health burden, necessitating reliable and cost-effective prognostic biomarkers for clinical decision-making. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, an integrated immune-nutrition marker, has emerged as a potential prognostic tool in various malignancies. This meta-analysis evaluated the prognostic value of the HALP score in patients with digestive system cancers.</p><p><strong>Methods: </strong>A systematic search was performed in PubMed, PMC, and Web of Science database for studies assessing HALP scores calculated from pre-treatment blood tests and reporting survival outcomes in patients with digestive system cancers. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled to evaluate the prognostic significance of the HALP score.</p><p><strong>Results: </strong>A total of 30 articles comprising 34 studies and 9,389 patients were included. High HALP scores were significantly associated with improved survival outcomes. The pooled HR for overall survival (OS) was 1.762 (95% CI: 1.570-1.977, P < 0.001), and similar results were found for disease-free survival (DFS) (HR = 1.841, 95% CI: 1.311-2.585, P < 0.001), recurrence-free survival (RFS) (HR = 1.583, 95% CI: 1.374-1.824, P < 0.001), cancer-specific survival (CSS) (HR = 1.930, 95% CI: 1.590-2.341, P < 0.001), and progression-free survival (PFS) (HR = 1.444, 95% CI: 1.068-1.954, P = 0.017). Subgroup analyses confirmed the robustness of these findings across different treatment strategies and cancer types. Sensitivity and bias analyses (P = 0.103) supported the reliability of these results.</p><p><strong>Conclusion: </strong>The HALP score is a promising prognostic biomarker for digestive system cancers, offering potential for clinical application in personalizing treatment strategies. Future studies should aim to standardize methodologies and validate HALP in prospective multicenter trials.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1577"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining compression therapy for the prevention of chemotherapy-induced peripheral neuropathy in breast cancer patients: a sub-analysis of patient-reported discomfort and usability.","authors":"Mai Okazaki, Aya Ueda, Akiko Iguchi-Manaka, Bryan J Mathis, Kensuke Shimada, Takeshi Machino, Takeshi Yamada, Hiroko Bando","doi":"10.1186/s12885-025-14921-3","DOIUrl":"10.1186/s12885-025-14921-3","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1567"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12522603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allostatic load and kidney cancer incidence and mortality: a genetic susceptibility and proteomic mediation analysis.","authors":"Chenhao Xu, Da Huo, Yanxu Liu, Qiyu Zhu, Junjie Zhao, Jiayu Liang, Xianding Wang","doi":"10.1186/s12885-025-14980-6","DOIUrl":"10.1186/s12885-025-14980-6","url":null,"abstract":"<p><strong>Background: </strong>Allostatic load (AL), reflecting chronic physiological stress across neuroendocrine, immune, and metabolic systems, may contribute to the onset and prognosis of multiple cancers via inflammation and stress-related injury. However, the associations between AL and kidney cancer (KC) remain unclear. And large-scale evidence linking AL to KC risk, prognosis, and molecular mechanisms is lacking.</p><p><strong>Methods: </strong>In this Prospective UK Biobank cohort study, 334,754 Participants were analyzed for KC incidence, 357 KC Patients for mortality, and 36,120 participants for proteomic mediation. Proteomic mediation was performed using Med4way analysis; protein trajectories were analyzed using locally weighted regression smoothing (LOESS) regression. The expression profiles of key mediator genes were validated by single-cell RNA sequencing. Enrichment analyses were conducted to characterize mediator proteins by biological pathways, tissue specificity, and cell-type distribution. An AL-mediated proteins-based prediction model was developed via LASSO-Cox regression.</p><p><strong>Results: </strong>During mean follow-up of 13.2 years, participants in the highest AL quintile had increased KC incidence (HR 1.70, 95% CI 1.38-2.10). Among KC patients, high AL was associated with increased mortality (HR 3.10, 95% CI 1.51-6.36). Proteins mediating AL-KC associations included HAVCR1, GDF15, TNFRSF11A, FSTL3, and CD83; HAVCR1 showed strongest mediation (72.69%) and distinct pre-diagnostic trajectory. Functional enrichment revealed these proteins were jointly involved in immune regulation, stress response, and epithelial signaling pathways. The predictive model incorporating NOS3, SULT2A1, HAVCR1, FSTL3, and sex achieved robust performance (10-year AUC 0.80) for KC Prediction.</p><p><strong>Conclusions: </strong>AL is associated with increased KC incidence and mortality, mediated through inflammatory and metabolic proteins. These findings underscore chronic physiological stress as a significant factor in KC pathogenesis, providing potential biomarkers for early risk assessment and targeted prevention.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1575"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of digital health on psychological well-being in parents of children with cancer: a systematic review and meta-analysis of randomized controlled trials.","authors":"Xiaoyu Yang, Shanshan Jiang, Xiaotong Wang, Rong Wang, Pan Li, Na Cao, Xinying Yu","doi":"10.1186/s12885-025-15050-7","DOIUrl":"10.1186/s12885-025-15050-7","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"1582"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12523181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}